ArticleLancet regional health. Americas2026
Ten-year subtype survival and systemic-therapy pathways analysis after breast-cancer recurrence in the LACRN MPBC multicountry cohort study.
Article in Lancet regional health. Americas, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
48 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: How treatment shapes survival after breast-cancer recurrence in Latin America remains poorly described. We extended follow-up of the Latin American Cancer Research Network cohort to quantify post-recurrence overall survival, describe systemic-therapy pathways, and assess the robustness of survival estimates to incomplete follow-up. Methods: We conducted a cohort study of women enrolled with stage I-III breast cancer at 31 centres in Argentina, Brazil, Chile, Mexico, and Uruguay between 2011 and 2014. Vital status and systemic treatments were updated from medical records to July 1, 2025. The main outcome was overall survival after recurrence, defined from first recurrence to death from any cause or censoring. Kaplan-Meier curves and log-rank tests compared survival by immunohistochemistry-defined subtype. Adjusted hazard ratios (HRs) with 95% confidence intervals (CIs) were estimated with a Firth-penalised Cox model. Sensitivity analyses included best-case and worst-case censoring, inverse-probability-of-censoring weighting, and Fine-Grey competing-risk regression. Systemic-therapy sequences were reconstructed for up to six lines. Findings: Vital status was updated for 970 of 1191 women (81.4%), and 162 had a documented first recurrence. Median overall survival after recurrence was 24.0 months (IQR 9.6-45.6). Compared with triple-negative breast cancer, adjusted HRs were 0.64 (95% CI 0.20-1.77) for hormone receptor-negative/HER2-positive disease, 0.54 (0.26-1.14) for hormone receptor-positive/HER2-negative disease, and 0.93 (0.39-2.20) for hormone receptor-positive/HER2-positive disease. Chemotherapy was the first-line regimen in 83 of 162 patients (51%), endocrine monotherapy in 55 of 162 (34%), and trastuzumab-pertuzumab-taxane or cyclin-dependent kinase 4 and 6 inhibitor-based regimens in eight of 162 (5%). Overall, 87 of 162 patients (54%) initiated second-line therapy. Interpretation: Adjusted subtype HRs were imprecise and should be interpreted cautiously. Steep treatment-line attrition, limited uptake of contemporary targeted therapies, and incomplete follow-up in some health-system settings indicate modifiable regional gaps in metastatic breast-cancer care. Funding: ASCO Conquer Cancer & Pfizer Competitive Grant for Quality Improvement (contract award No. 87534309); Center for Global Health at the United States-National Cancer Institute at the National Institutes of Health (contract award No. HHSN2612010000871/NO2-PC-2010-00087); Fogarty International Center, NIH, HHS; and Susan G. Komen for the Cure; in Argentina, Instituto Nacional del Cáncer (Ministry of Health), Fundación Argentina de Nanotecnología, Agencia Nacional de Promoción Científica y Tecnológica, CONICET (Ministry of Science, Technology, and Productive Innovation); Brazil, Ministério da Saúde (Ministry of Health); Chile, Instituto de Salud Pública (Public Health Institute) and Ministerio de Salud (Ministry of Health); and Mexico, Consejo Estatal de Ciencia y Tecnología de Jalisco (COECYTJAL) and Universidad de Sonora (University of Sonora).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.